Sales & Marketing News | pharmaphorum

News

FTC launches probe of Teva over ‘improper’ patents; report

Shares in Teva Pharmaceutical have dipped sharply after reports that the Federal Trade Commission (FTC) has opened an investigation into the company focusing on improperly listed patents in

News

AstraZeneca files rival to Pemgarda for COVID PrEP

AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP).

News

First intranasal Epipen alternative backed in EU

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray is close to approval in Europe after being recommended for approval by the EMA’s human medicines committee

News

Purdue’s bankruptcy plan in tatters as SCOTUS says no

The Supreme Court of the US has rejected a bankruptcy deal that would settle opioid litigation against Purdue Pharma, but also protect the Sackler family that controls the company from liab

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

England, Denmark back CSL’s haemophilia B gene therapy

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.

FTC launches probe of Teva over ‘improper’ patents; report

AstraZeneca files rival to Pemgarda for COVID PrEP

First intranasal Epipen alternative backed in EU

Purdue’s bankruptcy plan in tatters as SCOTUS says no

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

England, Denmark back CSL’s haemophilia B gene therapy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks